Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression signatures for lung adenocarcinoma

ABSTRACT: We used whole genome microarray expression profiling as a discovery platform to identify genes through 7 pairs lung adenocarcinoma tissues and normal tissues

ORGANISM(S): Homo sapiens

PROVIDER: GSE140797 | GEO | 2020/08/17

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Proteomic Identification of Lung Adenocarcinoma and Normal Lung Tissue

Project description:To identify proteomic of lung adenocarcinoma, we collected five pairs of lung adenocarcinoma and normal lung tissues from the clinic for analysis

2022-01-12 | PXD027008 | Pride

Identification of ubiquitinated proteins in lung adenocarcinoma and normal lung tissues

Project description:To identify ubiquitinated modified proteins of lung adenocarcinoma, we collected five pairs of lung adenocarcinoma and normal lung tissues from the clinic for analysis

2022-01-12 | PXD027001 | Pride

Human lung adenocarcinoma tissue LC-MS/MS

Project description:This project is a report of a chromosome-based human proteome project focused on chromosome 9 (Chr 9). To reveal missing proteins and undiscovered features in proteomes, LC-MS/MS analysis based identification and characterization were conducted on 5 pairs of lung adenocarcinoma tumors and adjacent non-tumor tissues.

2015-07-31 | PXD002523 | Pride

Development of lncRNA and Mrna expression signatures for pancreatic ductal adenocarcinoma

Project description:To further development of our lncRNA and mRNA expression approach to pancreatic ductal adenocarcinoma(PDAC), we have employed lncRNA and mRNA microarray expression profiling as a discovery platform to identify lncRNA and mRNA expression in pancreatic ductal adenocarcinoma.Human pancreatic ductal adenocarcinoma tissues and normal pancreatic tissues from PDAC donors and other duodenum diseases donors. analyze mRNA and lncRNA expression in pancreatic ductal adenocarcinoma (PDAC) by microarray platform

2014-11-18 | E-GEOD-57144 | biostudies-arrayexpress

Human lung adenocarcinoma tissue LC-MS/MS

2016-07-20 | MSV000079961 | MassIVE

Development of lncRNA and Mrna expression signatures for pancreatic ductal adenocarcinoma

2014-11-18 | GSE57144 | GEO

Gene expression signatures for lung adenocarcinoma

Project description:Gene expression signatures for lung adenocarcinoma

| PRJNA590980 | ENA

Ito2019 - gefitnib resistance of lung adenocarcinoma caused by MET amplification

Project description:The model is based on publication: Mathematical analysis of gefitinib resistance of lung adenocarcinoma caused by MET amplification Abstract: Gefitinib, one of the tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR), is effective for treating lung adenocarcinoma harboring EGFR mutation; but later, most cases acquire a resistance to gefitinib. One of the mechanisms conferring gefitinib resistance to lung adenocarcinoma is the amplification of the MET gene, which is observed in 5–22% of gefitinib-resistant tumors. A previous study suggested that MET amplification could cause gefitinib resistance by driving ErbB3-dependent activation of the PI3K pathway. In this study, we built a mathematical model of gefitinib resistance caused by MET amplification using lung adenocarcinoma HCC827-GR (gefitinib resistant) cells. The molecular reactions involved in gefitinib resistance consisted of dimerization and phosphorylation of three molecules, EGFR, ErbB3, and MET were described by a series of ordinary differential equations. To perform a computer simulation, we quantified each molecule on the cell surface using flow cytometry and estimated unknown parameters by dimensional analysis. Our simulation showed that the number of active ErbB3 molecules is around a hundred-fold smaller than that of active MET molecules. Limited contribution of ErbB3 in gefitinib resistance by MET amplification is also demonstrated using HCC827-GR cells in culture experiments. Our mathematical model provides a quantitative understanding of the molecular reactions underlying drug resistance.

2024-09-02 | BIOMD0000000827 | BioModels

tRF and tiRNA profiles in lung adenocarcinoma.

Project description:We investigate tRF and tiRNA profiles in lung adenocarcinoma and adjacent tissues using a NextSeq system. Total RNA was extracted from tissues and pretreated to remove the RNA modifications. In patients with lung adenocarcinoma, 338 types of tRFs and tiRNAs were detected via sequencing, 284 of which were not previously reported. Compared with the adjacent tissues, 17 types of tRFs and tiRNAs comprising 34 subtypes were found to be abnormally expressed in lung adenocarcinoma tissues, 20 of which were upregulated and 14 of which were downregulated. Finally, we show that tRF and tiRNA profiles in lung adenocarcinoma and adjacent tissues and identify several dysregulated tRFs and tiRNAs.

2021-05-19 | GSE168270 | GEO

Long non-coding RNA Expression Profiling in Lung Cancer = Lung Adenocarcinoma (Lu-T) and in normal lung tissue (Lu-N)

Project description:The expression of long non-coding RNAs - lncRNAs - was profiled in the lung adenocarcinoma patient samples (LUAD, Lu-T) and in normal lung tissues adjacent to tumors (Lu-N) using the Invitrogen NCode Human lncRNA Array Platform. will be published in: Anna Roth et al., Restoring LINC00673 expression triggers cellular senescence in lung cancer

2019-01-23 | GSE113852 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data